Urinary glucose excretion after dapagliflozin treatment: an exposure –response modeling comparison between Japanese and non‐Japanese patients diagnosed with Type 1 Diabetes Mellitus
ConclusionsThere was no difference in dapagliflozin exposure –response in Japanese and non‐Japanese patients with T1DM once differences in renal function, glycemic control and insulin dose reductions between studies were considered. Therefore, no dose adjustment is recommended in Japanese patients with T1DM.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Victor Sokolov,
Tatiana Yakovleva,
Shinya Ueda,
Joanna Parkinson,
David W. Boulton,
Robert C. Penland,
Weifeng Tang Tags: ORIGINAL ARTICLE Source Type: research
More News: Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Eating Disorders & Weight Management | Endocrinology | Forxiga | Insulin | Japan Health | Obesity | Parkinson's Disease | Study